ANN ARBOR, Mich., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that it has completed the buildout of its new Indiana production facility ahead of schedule. At this time the Company is installing the last piece of process equipment. Over the next week the Company will complete all pre-production checks and plans to start bringing in silkworms the week of August 15. This facility was initially established to fulfil the Company’s contract with the US Government. Additional production capacity from this facility will be used to satisfy material needs from industry collaborators and pending customers.
“The Indiana production center represents our first domestic production expansion and is a major step towards our near term goal of a fully self-contained US spider silk production facility,” said COO Jon Rice.
“The opening of this facility is an exciting moment for Kraig Labs and the future of commercially sustainable spider silk production,” said CEO and Founder Kim Thompson. “Our efforts in the lab have demonstrated the ability to recreate the incredible properties of spider silk, this facility now demonstrates that Kraig Labs can bring those materials to the market.”
To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.kraiglabs.com/newsletter.
For more information about Spider Silk, check it out at www.kraiglabs.com/spider-silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC (720) 288-8495 ir@KraigLabs.com
Source:Kraig Biocraft Laboratories, Inc.